Technical analysis of Immix Biopharma, Inc. (IMMX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors.
Price Performance
| 1 month | +0.93% |
| 3 months | +36.70% |
| Year-to-date | +127.92% |
| 1 year | +508.16% |
| 3 years | +349.81% |
52-Week Range
| 52-week High | $15.10 |
| 52-week Low | $1.94 |
| Avg Volume (90d) | 1.7M |
Technical Indicators
| SMA 50 | $11.29 |
| SMA 200 | $8.79 |
| Beta | 0.21 |
| 30-day Volatility (annualised) | 68.0% |
| Price vs SMA 50 | +5.6% |
| Price vs SMA 200 | +35.5% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $3.80 | |
| 2025-11 | $4.25 | +11.8% |
| 2025-12 | $5.23 | +23.1% |
| 2026-01 | $5.83 | +11.5% |
| 2026-02 | $8.07 | +38.4% |
| 2026-03 | $9.11 | +12.9% |
| 2026-04 | $8.93 | -2.0% |
| 2026-05 | $9.00 | +0.8% |
| 2026-06 | $10.31 | +14.6% |
| 2026-07 | $8.32 | -19.3% |
| 2026-08 | $14.03 | +68.6% |
| 2026-09 | $11.92 | -15.0% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | $0.05 | $88M |
| 2026-09-15 | | |
| 2026-09-15 | $0.14 | $2.28B |
| 2026-09-15 | | |
Price
| Price | $11.92 |
| Market Cap | $648M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.29 |
| EV / EBITDA | -13.21 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 25.13 |